drugset / Trial / NCT04631406
A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
Phase 1/2
Active not recruiting
30 enrolled
Gary Steinberg, MD, PhD
California Institute for Regenerative Medicine (CIRM) · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
Timeline
- Start
- 2021-01-04
- Primary completion
- 2025-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NR1 | Cell therapy | — | Other |